Clinical Research Directory
Browse clinical research sites, groups, and studies.
Investigation of Inflammation Using [C-11]-CS1P1
Sponsor: Tammie L. S. Benzinger, MD, PhD
Summary
There is a compelling need for a noninvasive imaging approach to measure S1P1 in both preclinical models of diseases and humans. PET measures of S1P1 expression is critical for elucidating the pathophysiological roles of S1P1 in neuroinflammation and neurodegeneration. The relevance of S1P1 in clinical disease has become readily apparent with the FDA approval of the S1P1 modulator FTY720 (fingolimod) for treating relapsing-remitting MS (RR-MS). MS is a chronic autoimmune, inflammatory disease caused by lymphocytic infiltration that leads to demyelinating neurodegenerative disease.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2020-11-02
Completion Date
2026-07-08
Last Updated
2025-08-07
Healthy Volunteers
Yes
Conditions
Interventions
[11C]-CS1P1
Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
Locations (1)
Washington University School of Medicine
St Louis, Missouri, United States